2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-121692
    (S)-Alprenolol 23846-71-1 98%
    (S)-Alprenolol is a potent and nonselective β-blocker.
    (S)-Alprenolol
  • HY-121726
    3HOI-BA-01 355428-84-1 98%
    3HOI-BA-01 is amTORinhibitor.3HOI-BA-01reduces infarct size and inducedautophagyin a murine myocardial ischemia/reperfusion injury model.
    3HOI-BA-01
  • HY-121746
    GW7845 196809-22-0 98%
    GW7845 is an orally active non-thiazolidinedione, tyrosine-derived PPARγ agonist. GW7845 is effective at inhibiting voltage-dependent calcium channels (VDCC) and relaxing pressurized arteries with IC50 of 3 μM by using Ba2+ as the charge carrier through VDCC. GW7845-induced apoptosis is mitochondria- and apoptosome-dependent. GW7845 induces rapid mitochondrial membrane depolarization and release of cytochrome c in primary pro-B cells and BU-11 cells.
    GW7845
  • HY-121776
    Nicomol 27959-26-8 98.40%
    Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids.
    Nicomol
  • HY-12177S
    Aliskiren-d6 hemifumarate 98%
    Aliskiren-d6 (hemifumarate) is a deuterium labeled Aliskiren hemifumarate. Aliskiren hemifumarate is a direct and orally active renin inhibitor with an IC50 of 1.5 nM.
    Aliskiren-d6 hemifumarate
  • HY-121985
    Protheobromine 50-39-5 98%
    Protheobromine is a cardiotonic and bronchodilator
    Protheobromine
  • HY-122040
    5-Chloro hydrochlorothiazide 5233-42-1 98%
    5-Chloro hydrochlorothiazide is a derivative of hydrochlorothiazide (HY-B0252), and has diuretic action.
    5-Chloro hydrochlorothiazide
  • HY-122048
    AR-C67085 164992-25-0 98%
    AR-C67085 (PSB 0413; FPL 67085) is a potent platelet P2T receptor antagonist with an pIC50 value of 8.60. AR-C67085 inhibits ADP-induced platelet aggregation.
    AR-C67085
  • HY-122178
    5-trans U-44069 330796-57-1 98%
    5-trans U-44069 is the trans isomer of the thromboxane receptor agonist U-44069 (HY-121825). 5-trans U-44069 inhibits prostaglandin E2 synthase activity.
    5-trans U-44069
  • HY-122211
    MRS2802 1047980-53-9 98%
    MRS2802 is a P2Y14 receptor agonist with an EC50 value of 63 nM. MRS2802 can effectively activate the P2Y14 receptor and may play a role in regulating platelet function. The selectivity and activity of MRS2802 are conducive to in-depth research on the biological functions and pharmacological properties of P2Y receptors. The development of MRS2802 provides a potential inhibitory strategy for the search for new antiplatelet compounds.
    MRS2802
  • HY-122221
    KUM 32 28717-34-2 98%
    KUM 32 is a potent antagonist of epinephrine-induced platelet aggregation. KUM 32 is an adenylate cyclase activity inhibitor. KUM 32 binds to the alpha 2 adrenergic receptor of human platelets.
    KUM 32
  • HY-122230
    UR-3216 220386-65-2 98%
    UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research.
    UR-3216
  • HY-122282
    AZ11657312 804561-22-6 98%
    AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure.
    AZ11657312
  • HY-122331
    Norbormide 991-42-4 98.91%
    Norbormide, a rodenticide, is a calcium entry blocker with a selective vasoconstrictor activity. Norbormide shows species- and tissue-specific, endothelium independent, and is restricted to the peripheral arteries of rat.
    Norbormide
  • HY-122364
    Bucumolol hydrochloride 36556-75-9 98%
    Bucumolol hydrochloride is a β-adrenergic receptor antagonist that can slow heart rate (negative chronotropic effect) and reduce cardiac contractility (negative inotropic effect). Bucumolol hydrochloride has antiarrhythmic and local anesthetic activity and can be used in the study of cardiovascular diseases.
    Bucumolol hydrochloride
  • HY-122423
    Desethylamiodarone 83409-32-9 98%
    Desethylamiodarone (N-Deethylamiodarone) is the major metabolite of antiarrhythmic compound Amiodarone (HY-14187). Desethylamiodarone has antiarrhythmic activity. Desethylamiodaron also induces cancer cell apoptosis.
    Desethylamiodarone
  • HY-122499
    Ciprostene calcium 81703-55-1 98%
    Ciprostene calcium is a prostacyclin analogue.Ciprostene calcium inhibits adenosine diphosphate-induced platelet aggregation. Ciprostene calcium can be used for research of peripheral vascular disease.
    Ciprostene calcium
  • HY-122537
    Arotinolol hydrochloride 68377-91-3 98%
    Arotinolol hydrochloride is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol hydrochloride also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol hydrochloride is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases.
    Arotinolol hydrochloride
  • HY-122542
    PPACK 71142-71-7 98%
    PPACK is potent, selective and irreversible thrombin inhibitor. PPACK can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK is also a plasminogen activator (rt-PA) inhibitor. PPACK can inhibit the binding of rt-PA to plasma protease inhibitors.
    PPACK
  • HY-122560
    VU0134992 755002-90-5 99.30%
    VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV.
    VU0134992
Cat. No. Product Name / Synonyms Application Reactivity